Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and the prolonged use of glucocorticoids is associated with side effects. The effect of the interleukin-6 receptor alpha inhibitor tocilizumab on the rates of relapse during glucocorticoid tapering was studied in patients with giant-cell arteritis.
Trial of Tocilizumab in Giant-Cell Arteritis / Stone, John H; Tuckwell, Katie; Dimonaco, Sophie; Klearman, Micki; Aringer, Martin; Blockmans, Daniel; Brouwer, Elisabeth; Cid, Maria C; Dasgupta, Bhaskar; Rech, Juergen; Salvarani, Carlo; Schett, Georg; Schulze Koops, Hendrik; Spiera, Robert; Unizony, Sebastian H; Collinson, Neil. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 377:4(2017), pp. 317-328. [10.1056/NEJMoa1613849]
Trial of Tocilizumab in Giant-Cell Arteritis
SALVARANI, CARLO;
2017
Abstract
Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and the prolonged use of glucocorticoids is associated with side effects. The effect of the interleukin-6 receptor alpha inhibitor tocilizumab on the rates of relapse during glucocorticoid tapering was studied in patients with giant-cell arteritis.
| File | Dimensione | Formato | |
|---|---|---|---|
|
nejmoa1613849.pdf
Accesso riservato
Tipologia:
Versione pubblicata dall'editore
Dimensione
268.09 kB
Formato
Adobe PDF
|
268.09 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
